Biointron Biological Inc., a CRO company, focused on antibody discovery, recently announced it had raised nearly 500 million RMB ($75M) for Series B funding. Led by more than ten investors, including Co-Stone Venture, Jifeng Ventures, TENYKIN Capital, HAITONG Ventures, Jiangsu Govtor, ALAN AMC, Joy Time, GAORONG Capital, OCTOBER Capital, West Shanghai Group, BEFOR Capital, among others. Prior investors FURONG Capital and CHENGSHU Capital also contributed to this round. The funding will mainly be used for the expansion of CRO service capacity, the production of advanced R&D and manufacturing service lines, and the continued expansion of business development abroad.
Founded in 2012, Biointron is a high-tech enterprise focusing on antibody discovery. The company provides customized services for researching, developing, and producing antibodies as drug candidates. Relying on the industry-leading ultra-high-throughput recombinant protein preparation platform, the company has established various platforms, including single B cell screening, antibody humanization, affinity maturation, VHH library generation, and stable cell line development. Biointron has served thousands of biopharma/biotech companies working on antibody drugs, IVD, vaccines, cell therapies, etc. The company has delivered over 70k+ antibodies for customers’ drug discovery. Biointron will continue to grow and make every effort to provide the best services to customers worldwide and help accelerate the process of antibody discoveries.
The blueprint of Shanghai R&D Center (in plan)
The blueprint of Taizhou Production Center (under construction)
About Co-stone
Co-Stone Venture has over 20 years of investment management experience. It is one of the earliest venture capital institutions in China. They have long been committed to equity investment and growth in local Chinese companies. By adhering to the investment philosophy of "centralized investment, focused service,” they cultivated and created industry leaders and sub-sectors leaders.
About Jifeng Ventures
Founded in 2015, Jifeng Ventures is a first-class venture capital institution focusing on the medical and health field. They empower enterprises and drive innovation through a full range of value-added services and a global perspective, aiming to bring long-term value to the development of the medical field and human health. Jifeng will always maintain the original intention of entrepreneurship and uphold the spirit of "professionalism, humility, and diligence." They will continue to serve entrepreneurs with strategic partnerships by helping enterprises establish themselves in China and expand their growth abroad.
About Tenykin Capital
TENYKIN Capital is a valued investor and navigator deeply engaged in the medical and health industry. The team has been engaged in investment management in the medical and health industry for over 20 years, focusing on key areas such as innovative drugs, new treatment technologies, precision medicine, and high-end medical devices. TENYKIN Capital has built a unique post-investment management system based on “1+1+N” such as “3+3” and “Hundred Days of Navigation.” Their professional post-investment value-added services have accelerated the advancement of the domestic medical and healthcare industry and equity participation. TENYKIN Capital follows its company value of “enterprise innovation, transformation, and leapfrog development.”
About Alan AMC
Founded in 2016, ALAN AMC is headquartered in Beijing and has established branches in Shanghai and Hong Kong. In the field of private equity business, ALAN AMC focuses on the investment opportunities of high-quality start-ups in the growth stage of development in the life, health, and information technology field. They have completed the investment arrangement of more than 50 high-quality enterprises in related fields. ALAN AMC always adheres to the investment philosophy of “industry and finance, international vision, and stable and long-term development” and is committed to providing professional and reliable capital services for partners and continuously creating long-term and stable investment returns for investors.
About Haitong Ventures
Established in 2012, Haitong Ventures is one of the first alternative investment companies owned by a security company approved by the China Securities Regulatory Commission. Adhering to the investment philosophy of "professionalism and focus", Haitong Ventures grasp the risk appetite of their own capital, led by value investment, and grow together with enterprises in the long run based on their innovation and creation strength, strategic management ability and market development potential.
About Joy Time Investment
Established in 2017, Joy Time Investment is a fast-growing private equity investment management institution with a current portfolio of nearly 2 billion RMB. The main investment industries include advanced equipment and manufacturing, new generation information technology, material, and energy, environmental protection and energy efficiency, medical and health industries, and growing innovative and entrepreneurial enterprises that integrate traditional businesses with new technologies.
About Jiangsu Govtor
After 20 years of development, Jiangsu Govtor has become a leading venture capital institution in China. They are a professional institution covering venture capital, new third board private placement, securities investment, and mergers and acquisitions for domestic and overseas investment. The company pays equal attention to its capital investment and asset management portfolio, with a registered capital of 1 billion yuan and over 5 billion yuan in total asset management. They have an experienced team with extensive knowledge of the domestic and foreign capital market and focus on providing comprehensive solutions for enterprises to enhance corporate value.
About GAORONG Capital
After 20 years of development, Jiangsu Govtor has become a leading venture capital institution in China. They are a professional institution covering venture capital, new third board private placement, securities investment, and mergers and acquisitions for domestic and overseas investment. The company pays equal attention to its capital investment and asset management portfolio, with a registered capital of 1 billion yuan and over 5 billion yuan in total asset management. They have an experienced team with extensive knowledge of the domestic and foreign capital market and focus on providing comprehensive solutions for enterprises to enhance corporate value.
About CS Capital
ChengShu Capital was established in 2010, focusing on growth-stage investment in big health, focusing on growth-stage and early-stage investment opportunities in consumer medical and life sciences. The management team of ChengShu Capital is well versed in the law of corporate growth and has rich industry resources and capital market experience. Its mission is to continuously empower the invested companies towards growth and create long-term sustainable value for investors.
About October Capital
October Capital is a fast-growing and cutting-edge private equity investment management institution founded by several senior executives from well-known domestic securities firms, equity investment, and investment banking institutions. October Capital has three management platforms and currently manages more than ten private equity investment funds, with a stock portfolio of more than 3 billion yuan. Since 2016, nearly 50 investment projects have been funded, more than 20 companies have successfully listed on A shares, and more than ten new projects have been listed.
About FURONG Capital
Founded in 2014, FURONG Capital is a professional innovation investment and innovation service organization focusing on early and mid-term projects in life and health, semiconductors, and new energy materials. They are committed to promoting the industrialization of scientific and technological achievements, innovation, and entrepreneurship of high-level talents by observing the philosophy of "research-driven" and "investment in early-stage investment.” FURONG actively serves the integrated development of the Yangtze River Delta region, Shanghai's construction of a globally influential technology innovation center, and other national innovation-driven development strategies.
About West Shanghai Group
West Shanghai Group was established in 2002. The company participates in the investment of multiple projects in the form of direct investment or special funds. With the tenet of "everything starts with integrity," the company adheres to the development idea of "finance + industry.” It is currently implementing the "14th Five-Year Plan" development strategy, striving to become a modern service provider with quality, connotation, reliability, and sustainable development.
About BEFOR Capital
BEFOR Capital was established in October 2015, focusing on growth-stage investment opportunities in consumption upgrading, advanced technology, and modern services. Up to now, their portfolio is close to 3 billion yuan, and they have invested in nearly 40 high-quality enterprises in sub-sectors. The fund discovers value through extensive industry research, creates value through empowerment, and is committed to becoming a capital strategic partner that helps entrepreneurs achieve remarkable innovations.